727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours

• Rohit Joshi,
• Sharron Gargosky,
• Victoria Atkinson,
• James A Lederer,
• Jeffrey Goh,
• Vineet Kwatra,
• Warren Joubert,
• Meena Okera,
• Sarwan Bishnoi,
• Frank Borriello,
• Ganessan Kitchenadasse,
• George Nisyrios

Affiliations

Rohit Joshi

1Cancer Research SA, Adelaide, SA, Australia

Sharron Gargosky

3Alloplex Biotherapeutics, Inc, Woburn, MA, USA

Victoria Atkinson

5Princess Alexandra Hospital, Woolloongabba, QLD, Australia

James A Lederer

8Alloplex Biotherapeutics Inc, Woburn, MA, USA

Jeffrey Goh

2Gallipoli Medical Research Foundation, Brisbane, SA, Australia

Vineet Kwatra

1Cancer Research SA, Adelaide, SA, Australia

Warren Joubert

6Gallipoli Research Foundation, Brisbane, QLD, Australia

Meena Okera

7Cancer Research South Australia (CRSA), Adelaide, SA, Australia

Sarwan Bishnoi

7Cancer Research South Australia (CRSA), Adelaide, SA, Australia

Frank Borriello

3Alloplex Biotherapeutics, Inc, Woburn, MA, USA

Ganessan Kitchenadasse

4Southern Oncology Clinical Research Organisation, Adelaide, SA, Australia

George Nisyrios

4Southern Oncology Clinical Research Organisation, Adelaide, SA, Australia